Management of femoral fracture in a patient with essential thrombocythemia treated with plateletpheresis and intramedullary rod fixation, followed by hydroxyurea: a case report.
We describe the management of a patient with a femoral fracture who had asymptomatic essential thrombocythemia. When the diagnosis of essential thrombocythemia was made, the patient was treated with plateletpheresis to reduce the platelet count before intramedullary rod fixation of his fracture. His postoperative management included the examination of his peripheral blood as well as bone marrow, which confirmed that the cause of his elevated platelet count was due to JAK2 V617F mutation that is treated by hydroxyurea and aspirin after being discharged from the hospital.
Plastic Surgery, Biomedical Engineering, and Emergency Medicine, University of Virginia Health Systems, Charlottesville, VA, USA. richardedlichmd@gmail.com
Richard F
RF
Edlich
William B
WB
Long
Amy A
AA
Cochran
Angela R
AR
Kelley
Dayna R
DR
Woode
Jill Amanda
JA
Greene
Gary W
GW
Takahashi
D000368:Aged; D015897:Comorbidity; D004632:Emergency Medical Services; D005264:Femoral Fractures / Q000453:epidemiology* / Q000601:surgery*; D005594:Fracture Fixation, Intramedullary; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D053614:Janus Kinase 2 / Q000235:genetics; D008297:Male; D009154:Mutation; D019384:Nucleic Acid Synthesis Inhibitors / Q000627:therapeutic use; D010976:Platelet Count; D010983:Plateletpheresis; D013920:Thrombocythemia, Essential / Q000453:epidemiology* / Q000235:genetics / Q000628:therapy
D019384:Nucleic Acid Synthesis Inhibitors; C507924:JAK2 protein, human; D053614:Janus Kinase 2; D006918:Hydroxyurea